These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37131549)

  • 21. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
    Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape.
    Yang L; Li J; Guo S; Hou C; Liao C; Shi L; Ma X; Jiang S; Zheng B; Fang Y; Ye L; He X
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India).
    Sanches PRS; Charlie-Silva I; Braz HLB; Bittar C; Freitas Calmon M; Rahal P; Cilli EM
    J Virus Erad; 2021 Sep; 7(3):100054. PubMed ID: 34548928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Basis of Mink ACE2 Binding to SARS-CoV-2 and Its Mink-Derived Variants.
    Su C; He J; Han P; Bai B; Li D; Cao J; Tian M; Hu Y; Zheng A; Niu S; Chen Q; Rong X; Zhang Y; Li W; Qi J; Zhao X; Yang M; Wang Q; Gao GF
    J Virol; 2022 Sep; 96(17):e0081422. PubMed ID: 36000849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity.
    Liu H; Wei P; Kappler JW; Marrack P; Zhang G
    Front Immunol; 2022; 13():825256. PubMed ID: 35154144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.
    Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC
    Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants.
    Tchesnokova V; Kulasekara H; Larson L; Bowers V; Rechkina E; Kisiela D; Sledneva Y; Choudhury D; Maslova I; Deng K; Kutumbaka K; Geng H; Fowler C; Greene D; Ralston J; Samadpour M; Sokurenko E
    J Clin Microbiol; 2021 Oct; 59(11):e0092121. PubMed ID: 34379531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies.
    Rattanapisit K; Bulaon CJI; Khorattanakulchai N; Shanmugaraj B; Wangkanont K; Phoolcharoen W
    PLoS One; 2021; 16(8):e0253574. PubMed ID: 34379620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
    Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
    Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
    Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
    J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.
    Villoutreix BO; Calvez V; Marcelin AG; Khatib AM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recognition through GRP78 is enhanced in the UK, South African, and Brazilian variants of SARS-CoV-2; An in silico perspective.
    Ibrahim IM; Elfiky AA; Elgohary AM
    Biochem Biophys Res Commun; 2021 Jul; 562():89-93. PubMed ID: 34049205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Epidemiology of SARS-CoV-2: The Dominant Role of Arginine in Mutations and Infectivity.
    Ridgway H; Ntallis C; Chasapis CT; Kelaidonis K; Matsoukas MT; Plotas P; Apostolopoulos V; Moore G; Tsiodras S; Paraskevis D; Mavromoustakos T; Matsoukas JM
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851526
    [No Abstract]   [Full Text] [Related]  

  • 38. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2.
    Wang M; Yan H; Chen L; Wang Y; Li L; Zhang H; Miao L
    PLoS One; 2023; 18(5):e0285722. PubMed ID: 37200310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
    Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
    Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.